Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
05/2003
05/20/2003US6566352 Administering alpha -hydroxy-2-methylene-19-nor-pregnacalciferol compound for therapy of psoriasis
05/20/2003US6566346 Oral skin improving agent, skin improving method, and food composition for improving skin
05/20/2003US6566127 Enzymatic nucleic acid for use in the treatment of tumors, vision defects, arthritis and skin disorders
05/20/2003US6565880 Antiinflammatory agents
05/20/2003US6565848 Cadherin-like asymmetry protein-1, and methods for its use
05/20/2003CA2070524C Retinoids substituted by a dithiane cyclic and their use, process for the preparation of these compounds, cosmetic and pharmaceutical compositions containing them and therapeutical use of said compositions
05/15/2003WO2003040366A2 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003WO2003040358A1 Somatic cell derived embryonic stem cells and its differentiated cells
05/15/2003WO2003040329A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003WO2003040188A1 Antibody stimulating il-1ra production
05/15/2003WO2003040174A2 Substituted amino ketone compounds
05/15/2003WO2003040144A2 Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
05/15/2003WO2003040131A1 Aminopyrimidines and pyridines
05/15/2003WO2003040119A1 Angiogenesis inhibitors
05/15/2003WO2003040118A1 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
05/15/2003WO2003040117A1 Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
05/15/2003WO2003040115A1 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase
05/15/2003WO2003040108A1 Quinazoline derivatives as antitumor agents
05/15/2003WO2003040102A1 Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors
05/15/2003WO2003040101A1 Anthranilic acid amides and pharmaceutical use thereof
05/15/2003WO2003040098A1 Novel metalloproteinase inhibitors
05/15/2003WO2003040080A2 Lipoxin a4 analogs
05/15/2003WO2003039597A1 Compositions comprising a photosensitizer and a skin-penetration enhancer and their use in photodynamic treatment
05/15/2003WO2003039596A1 Photodynamic therapy for the treatment of hair loss
05/15/2003WO2003039585A1 Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
05/15/2003WO2003039580A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003WO2003039562A1 Composition and method
05/15/2003WO2003039559A1 Pharmaceutical combinatons comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application
05/15/2003WO2003039550A1 Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
05/15/2003WO2003039548A1 Hydrazono-malonitriles
05/15/2003WO2003039544A1 Naphtyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
05/15/2003WO2003039538A1 Composition containing a flavonoid glycone and method for using same as anti-proliferative
05/15/2003WO2003039510A1 Compositions containing oils having a specific gravity higher than the specific gravity of water
05/15/2003WO2003039509A1 Use of oligosaccharides in cosmetic or dermatological compositions for stimulating adherence of keratinocytes on the dermoepidermal junction major proteins and restoring epidermal cohesion
05/15/2003WO2003039478A2 Method and apparatus for the stimulation of hair growth
05/15/2003WO2003039473A2 Method for treating or preventing inflammatory diseases
05/15/2003WO2003039472A2 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
05/15/2003WO2003039452A2 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003WO2003039448A2 Polymer-structured composition containing lipophilic amino acid derivatives
05/15/2003WO2003039447A2 Composition containing an amino acid n-acylated ester and a polyamide-structured uv filter
05/15/2003WO2003039446A2 Use of 2-amino-4-pyridylmethyl-thiazoline derivatives as inhibitors of inducible no-synthase
05/15/2003WO2003039444A2 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
05/15/2003WO2003039442A2 Use of an extract from the vigna aconitifolia plant in a cosmetic and/or dermopharmaceutical composition
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039231A2 Compounds and methods for treating transplant rejection
05/15/2003WO2003020754A3 Inhibition of replication factor c
05/15/2003WO2002100836A3 Compounds, compositions and methods for modulating beta-amyloid production
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002058679A3 Antiangiogenic compounds and an assay for inhibitors of cell invasion
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2002018407A9 Antisense oligonucleotides against vanilloid receptor 1
05/15/2003WO2002000611A8 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
05/15/2003WO2001079173A3 Enamine derivatives as cell adhesion molecules
05/15/2003US20030092917 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092891 Expressed ligand - vascular intercellular signalling molecule
05/15/2003US20030092771 Inhibitors of transcription factor NF-kappaB
05/15/2003US20030092764 Oxidation resistance
05/15/2003US20030092762 Anti-inflammatory nitro and thia-fatty acids
05/15/2003US20030092754 External preparation for skin diseases containing nitroimidazole
05/15/2003US20030092748 Benzenesulfonamide derivatives and their use as MEK inhibitors
05/15/2003US20030092744 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092727 Hydroxamic and carboxylic acid derivatives
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092717 Inhibitors of p38 kinase
05/15/2003US20030092714 Heterocyclic inhibitors of ERK2 and uses thereof
05/15/2003US20030092713 Antiinflammatory agents; antiallergens; psychological disorders
05/15/2003US20030092712 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092704 Novel arylglycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
05/15/2003US20030092703 Caspase inhibitors and uses thereof
05/15/2003US20030092702 Antiinflammatory agents; autoimmune disease; autoimmune diseases
05/15/2003US20030092678 Muscle relaxants, controlling immunology, sexual disorders, rheumatic diseases
05/15/2003US20030092675 Skin treatment using a new retinoid
05/15/2003US20030092638 Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
05/15/2003US20030092631 IGF antagonist peptides
05/15/2003US20030092630 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases
05/15/2003US20030092624 Denaturant (boiling and/or detergent) stable; various uses including de-aggregating and/or preventing aggregation of an aggregating protein such as beta-amyloid or prions, restoring enzyme activity, and immunization using fusion protein
05/15/2003US20030092602 Use of neurokinin receptor antagonists to treat androgen-dependent diseases
05/15/2003US20030092163 Probiotic bifidobacterium strains
05/15/2003US20030092130 DNA encoding polypeptides having interferon-gamma inducing activity
05/15/2003US20030092059 Human antibodies that bind human TNFalpha
05/15/2003US20030092054 Protein complexes and assays for screening anti-cancer agents
05/15/2003US20030092044 Nucleotide sequences coding polypeptide for use in the treatment of apoptosis, inflammatory and autoimmune disorders
05/15/2003US20030092030 Wit 3.0, a novel gene to control soft tissue wound healing
05/15/2003US20030091974 Detecting compounds capable of exhausting mast cells; culture mast cells, incubate with modulator, measure mast cell death, classify compound
05/15/2003US20030091667 Clear, colorless solution; mixture of surfactant and microbiocide
05/15/2003US20030091659 Plant extracts; active materials
05/15/2003US20030091650 Ratite oil as a topical adjuvant and transdermal carrier
05/15/2003US20030091639 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
05/15/2003US20030091620 Transdermal drug delivery systems containing quaternary ammonium salts and methods of using the same
05/15/2003US20030091611 Antiproliferative agents ; antiinflammatory agents; insertable stent
05/15/2003US20030091607 Wrinkle resistance; cosmetics
05/15/2003US20030091567 Antiinflammatory agents; anticancer agents
05/15/2003US20030091566 Antitumor agents
05/15/2003US20030091559 Biocompatibility; liquid phase
05/15/2003US20030091558 Storage-stable fibrinogen solutions
1 ... 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 ... 1065